Download PDF
CC BY-NC-ND 4.0 · Int J Sports Med 2023; 44(03): 206-214
DOI: 10.1055/a-1960-2543
Training & Testing

Changes in Health-related Parameters Associated with Sports Performance Enhancement Drugs

Magdalena Wiacek
1   Faculty of Medical and Health Sciences, Kazimierz Pulaski University of Technology and Humanities in Radom, Radom, Poland
,
Bartosza Trąbka
2   Faculty of Physical Culture, Gdansk University of Physical Education and Sport, Gdansk, Poland
,
Ryszard Tomasiuk
1   Faculty of Medical and Health Sciences, Kazimierz Pulaski University of Technology and Humanities in Radom, Radom, Poland
,
Igor Z Zubrzycki
3   Biometry and Mathematics, Botswana University of Agriculture and Natural Resources, Gaborone, Botswana
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The purpose of this study was to evaluate changes in health-related parameters caused by the administration of anabolic-androgenic steroids and “fat-burning drugs” during a 6-month competition preparation period. The physiological, biochemical, and anthropometric parameters studied included serum cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, aspartate aminotransferase, alanine transaminase, bilirubin, body mass, and percentage of total body fat. Changes in the parameters studied were analyzed at monthly intervals during six months of preparation for competition. The study revealed a continuous increase in body mass, accompanied by a decrease in body fat percentage to the physiologically essential level. Total cholesterol levels remined in the desirable concentration range. The mean levels of triglycerides fluctuated between borderline high and high. Mean high-density lipoprotein cholesterol levels remained within the low range, while low-density lipoprotein cholesterol fluctuated between near-optimal / above-optimal, borderline high, and high levels. Serum levels of aspartate aminotransferase and alanine transaminase remained within the high concentration. The bilirubin concentration remained in the desirable range. The blood nitrogen urea concentration fluctuated between normal and elevated levels. Sports-enhancing drugs analyzed in this study do not have an immediate detrimental impact on the selected biochemical, physiological, and anthropometric parameters that define health.

Key words

sport enhancement drugs - professional sports - bodybuilding


Publication History

Received: 16 March 2022

Accepted: 25 July 2022

Article published online:
02 December 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Celotti F, Negri Cesi P. Anabolic steroids: A review of their effects on the muscles, of their possible mechanisms of action and of their use in athletics. J Steroid Biochem Mol Biol 1992; 43: 469-477
    CrossrefPubMedGoogle Scholar
  • 2 Phillips SM, Van Loon LJ. Dietary protein for athletes: From requirements to optimum adaptation. J Sports Sci 2011; 29: S29-S38
    CrossrefPubMedGoogle Scholar
  • 3 Tipton KD, Wolfe RR. Exercise, protein metabolism, and muscle growth. Int J Sport Nutr Exerc Metab 2001; 11: 109-132
    CrossrefPubMedGoogle Scholar
  • 4 Brand-Saberi B. Genetic and epigenetic control of skeletal muscle development. Ann Anat 2005; 187: 199-207
    CrossrefPubMedGoogle Scholar
  • 5 Simon P, Striegel H, Aust F. et al. Doping in fitness sports: Estimated number of unreported cases and individual probability of doping. Addiction 2006; 101: 1640-1644
    CrossrefPubMedGoogle Scholar
  • 6 Havnes IA, Jorstad ML, Wisloff C. Anabolic-androgenic steroid users receiving health-related information; health problems, motivations to quit and treatment desires. Subst Abuse Treat Prev Policy 2019; 14: 20
    CrossrefPubMedGoogle Scholar
  • 7 Win-May M, Mya-Tu M. The effect of anabolic steroids on physical fitness. J Sports Med Phys Fitness 1975; 15: 266-271
    PubMedGoogle Scholar
  • 8 Hoffman JR, Ratamess NA. Medical issues associated with anabolic steroid use: Are they exaggerated?. J Sports Sci Med 2006; 5: 182-193
    PubMedGoogle Scholar
  • 9 Boregowda K, Joels L, Stephens JW. et al. Persistent primary hypogonadism associated with anabolic steroid abuse. Fertil Steril 2011; 96: e7-e8
    CrossrefPubMedGoogle Scholar
  • 10 Geraci MJ, Cole M, Davis P. New onset diabetes associated with bovine growth hormone and testosterone abuse in a young body builder. Hum Exp Toxicol 2011; 30: 2007-2012
    CrossrefPubMedGoogle Scholar
  • 11 Kienbacher G, Maurer-Ertl W, Glehr M. et al. [A case of a tumor simulating expansion caused by anabolic androgen steroids in body building]. Sportverletz Sportschaden 2007; 21: 195-198
    PubMedGoogle Scholar
  • 12 Voelcker V, Sticherling M, Bauerschmitz J. Severe ulcerated ‘bodybuilding acne’ caused by anabolic steroid use and exacerbated by isotretinoin. Int Wound J 2010; 7: 199-201
    CrossrefPubMedGoogle Scholar
  • 13 Vorona E, Nieschlag E. Adverse effects of doping with anabolic androgenic steroids in competitive athletics, recreational sports and bodybuilding. Minerva Endocrinol 2018; 43: 476-488
    CrossrefPubMedGoogle Scholar
  • 14 Zubrzycki IZ MW. White book on steroids. Independently published; 2017.
    PubMedGoogle Scholar
  • 15 Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34: 513-554
    CrossrefPubMedGoogle Scholar
  • 16 Wiacek M, Trabka B, Markuszewski L. et al. Relations between performance enhancement drugs and health-defining parameters during the competition preparation period of World-class bodybuilders. Research Square 2021; DOI: 10.21203/rs.3.rs-779161/v1.
    CrossrefPubMedGoogle Scholar
  • 17 Bachorik PS, Kwiterovich PO. Apolipoprotein measurements in clinical biochemistry and their utility vis-a-vis conventional assays. Clin Chim Acta 1988; 178: 1-34
    CrossrefPubMedGoogle Scholar
  • 18 Bachorik PS, Lovejoy KL, Carroll MD. et al. Measurement of apolipoproteins A-I and B during the National Health and Nutrition Examination Survey (NHANES) III. Clin Chem 1994; 40: 1915-1920
    CrossrefPubMedGoogle Scholar
  • 19 Baim S, Wilson CR, Lewiecki EM. et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: Position paper of the International Society for Clinical Densitometry. J Clin Densitom 2005; 8: 371-378
    CrossrefPubMedGoogle Scholar
  • 20 Zipf G, Chiappa M, Porter KS. et al. National health and nutrition examination survey: Plan and operations, 1999-2010. Vital Health Stat 1 2013; 1-37
    PubMedGoogle Scholar
  • 21 Curtin LR, Mohadjer LK, Dohrmann SM. et al. The National Health and Nutrition Examination Survey: Sample Design, 1999-2006. Vital Health Stat 2 2012; 1-39
    PubMedGoogle Scholar
  • 22 Wolf ST, Jablonski NG, Kenney WL. Examining “race” in physiology. Am J Physiol Heart Circ Physiol 2020; 319: H1409-H1413
    CrossrefPubMedGoogle Scholar
  • 23 National Health and Nutrition Examination Survey. ANTHROPOMETRY PROCEDURES MANUAL. In Internet: https://wwwn.cdc.gov/nchs/data/nhanes/2003-2004/manuals/BM.pdf;(10/11/2021)
    PubMed
  • 24 Lipoprotein Analytical LaboratoryLaboratory Procedure Manual. In Internet: https://wwwn.cdc.gov/nchs/data/nhanes/1999-2000/ labmethods/lab13_met_lipids.pdf; (1/10/2015)
    PubMed
  • 25 Collaborative Laboratory Services LLC. Laboratory Procedure Manual. In Internet: https://wwwn.cdc.gov/nchs/data/nhanes/2003-2004/labmethods/l40_c_met_aspartate_aminotransferase.pdf (20/5/2015)
    PubMed
  • 26 Collaborative Laboratory Services LLC. Laboratory Procedure Manual. In Internet: https://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/bil_biopro_e_met_dxc800.pdf;(20/5/2015)
    PubMed
  • 27 Collaborative Laboratory Services LLC. Laboratory Procedure Manual. In Internet: https://wwwn.cdc.gov/nchs/data/nhanes/2003-2004/labmethods/l40_c_met_blood_urea_nitrogen.pdf (20/5/2015)
    PubMed
  • 28 National Institute of Health. BODY COMPOSITION PROCEDURES MANUAL. In Internet: https://wwwn.cdc.gov/nchs/data/nhanes/2003-2004/manuals/BC.pdf (1/4/2013)
    PubMed
  • 29 Shapiro SS, Wilk MB, Chen HJ. A comparative study of various tests for normality. J Am Stat Assoc 1968; 63: 1343-1372
    CrossrefPubMedGoogle Scholar
  • 30 Gastwirth J, Gel Y, Miao W. The impact of levene’s test of equality of variances on statistical theory and practice. Statist Sci 2009; 24: 343-360
    CrossrefPubMedGoogle Scholar
  • 31 Reed JF, Stark DB. Robust alternatives to traditional analysis of variance: Welch W*, James JI*, James JII*, Brown-Forsythe BF*. Comput Methods Programs Biomed 1988; 26: 233-237
    CrossrefPubMedGoogle Scholar
  • 32 Welch BL. On linear combinations of several variances. J Am Stat Assoc 1956; 51: 132-148
    CrossrefPubMedGoogle Scholar
  • 33 Games PA, Howell JF. Pairwise multiple comparison procedures with unequal n’s and/or variances: a monte carlo study. J Educ Behav Stat 1976; 1: 113-125
    PubMedGoogle Scholar
  • 34 Manore M, Meyer NL, Thompson J. Sport Nutrition for Health and Performance. 2nd ed. Champaign, IL: Human Kinetics; 2009
    Google Scholar
  • 35 A Round Table. Body composition. The Physician and Sportsmedicine 1986: 14: 144–162
  • 36 Mohamad NV, Soelaiman IN, Chin KY. A concise review of testosterone and bone health. Clin Interv Aging 2016; 11: 1317-1324
    CrossrefPubMedGoogle Scholar
  • 37 Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. (1990). In Internet: https://www.ahajournals. org/doi/pdf/10.1161/01.cir.83.6.2154; (20/11/2021)
    PubMed
  • 38 Siest Gr, Schiele Fo, Galteau M-M et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 1975; 21: 1077-1087
    CrossrefPubMedGoogle Scholar
  • 39 Witek K, Ścisłowska J, Turowski D. et al. Total bilirubin in athletes, determination of reference range. Biol Sport 2017; 34: 45-48
    CrossrefPubMedGoogle Scholar
  • 40 Jacobson SA, Jacobson SA. Clinical Laboratory Medicine for Mental Health Professionals. 1st ed. Arlington, Virginia: American Psychiatric Association Publishing; 2017
    Google Scholar
  • 41 Lippi G, Franchini M, Guidi GC. Doping in competition or doping in sport?. Br Med Bull 2008; 86: 95-107
    CrossrefPubMedGoogle Scholar
  • 42 Gleaves J, Petróczi A, Folkerts D. et al. Doping prevalence in competitive sport: evidence synthesis with “best practice” recommendations and reporting guidelines from the wada working group on doping prevalence. Sports Med 2021; 51: 1909-1934
    CrossrefPubMedGoogle Scholar
  • 43 Tenório MCC, Paz CL, Valladares F. et al. Effects of low-to-moderate doses of anabolic steroids on lipid profile and muscle hypertrophy in resistance training practitioners: a systematic review with meta-analysis. Int J Cardiovasc Sci 2021; 34: 531-541
    PubMedGoogle Scholar
  • 44 Halstead LS, Groah SL, Libin A. et al. The effects of an anabolic agent on body composition and pulmonary function in tetraplegia: a pilot study. Spinal Cord 2010; 48: 55-59
    CrossrefPubMedGoogle Scholar
  • 45 Gapstur SM, Gann PH, Kopp P. et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1041-1047
    PubMedGoogle Scholar
  • 46 Simon D, Preziosi P, Barrett-Connor E. et al. The influence of aging on plasma sex hormones in men: the telecom study. Am J Epidemiol 1992; 135: 783-791
    CrossrefPubMedGoogle Scholar
  • 47 Leifke E, Gorenoi V, Wichers C. et al. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf) 2000; 53: 689-695
    CrossrefPubMedGoogle Scholar
  • 48 Ng Tang Fui M, Hoermann R, Nolan B. et al. Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial. Sci Rep 2018; 8: 9099
    CrossrefPubMedGoogle Scholar
  • 49 Snyder PJ, Peachey H, Hannoush P. et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-1972
    PubMedGoogle Scholar
  • 50 Lunt M, Felsenberg D, Adams J. et al. Population-based geographic variations in DXA bone density in Europe: The EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 1997; 7: 175-189
    CrossrefPubMedGoogle Scholar
  • 51 Imboden MT, Welch WA, Swartz AM. et al. Reference standards for body fat measures using GE dual energy x-ray absorptiometry in Caucasian adults. PLoS One 2017; 12: e0175110
    CrossrefPubMedGoogle Scholar
  • 52 Tagarakis CV, Bloch W, Hartmann G. et al. Testosterone-propionate impairs the response of the cardiac capillary bed to exercise. Med Sci Sports Exerc 2000; 32: 946-953
    CrossrefPubMedGoogle Scholar
  • 53 Baggish AL, Weiner RB, Kanayama G. et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation 2017; 135: 1991-2002
    CrossrefPubMedGoogle Scholar
  • 54 Tarchalski J, Guzik P, Wysocki H. Correlation between the extent of coronary atherosclerosis and lipid profile. Mol Cell Biochem 2003; 246: 25-30
    CrossrefPubMedGoogle Scholar
  • 55 Büttner A, Thieme D. Side effects of anabolic androgenic steroids: pathological findings and structure-activity relationships. Handb Exp Pharmacol 2010; 195: 459-484
    CrossrefPubMedGoogle Scholar
  • 56 Stimac D, Milić S, Dintinjana RD. et al. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002; 35: 350-352
    CrossrefPubMedGoogle Scholar
  • 57 Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol 2007; 5: 809-812
    CrossrefPubMedGoogle Scholar
  • 58 Baird MF, Graham SM, Baker JS. et al. Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery. J Nutr Metab 2012; 2012: 960363
    CrossrefPubMedGoogle Scholar
  • 59 Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). In Internet: (20/11/2021)
    PubMed
  • 60 Oda SS, El-Ashmawy IM. Adverse effects of the anabolic steroid, boldenone undecylenate, on reproductive functions of male rabbits. Int J Exp Pathol 2012; 93: 172-178
    CrossrefPubMedGoogle Scholar
  • 61 Tousson E, El-Moghazy M, Massoud A. et al. Physiological and biochemical changes after boldenone injection in adult rabbits. Toxicol Ind Health 2016; 32: 177-182
    CrossrefPubMedGoogle Scholar
  • 62 O’Connor JJ, Stillions MC, Reynolds WA. et al. Evaluation of boldenone undecylenate as an anabolic agent in horses. Can Vet J 1973; 14: 154-158
    PubMedGoogle Scholar
  • 63 Kung AW, Pang RW, Lauder I. et al. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem 1995; 41: 226-231
    CrossrefPubMedGoogle Scholar
  • 64 Aviram M, Luboshitzky R, Brook JG. Lipid and lipoprotein pattern in thyroid dysfunction and the effect of therapy. Clin Biochem 1982; 15: 62-66
    CrossrefPubMedGoogle Scholar
  • 65 Dullaart RPF, van Doormaal JJ, Hoogenberg K. et al. Triiodothyronine rapidly lowers plasma lipoprotein (a) in hypothyroid subjects. Neth J Med 1995; 46: 179-184
    CrossrefPubMedGoogle Scholar
  • 66 Ribeiro MO. Effects of thyroid hormone analogs on lipid metabolism and thermogenesis. Thyroid 2008; 18: 197-203
    CrossrefPubMedGoogle Scholar
  • 67 Ajala MO, Ogunro PS, Fasanmade OA. Relationship between liver function tests and thyroid hormones in thyroid disorders. Niger Postgrad Med J 2013; 20: 188-192
    CrossrefPubMedGoogle Scholar
  • 68 Sharma S, Garg A. Clenbuterol induced changes in cholesterol and triglyceride levels of gastrocnemius, pectoralis and heart of rat under work induced stress. Indian J Exp Biol 2003; 41: 1452-1455
    PubMedGoogle Scholar
  • 69 Hartung R, Gerth J, Fünfstück R. et al. End-stage renal disease in a bodybuilder: a multifactorial process or simply doping?. Nephrol Dial Transplant 2001; 16: 163-165
    CrossrefPubMedGoogle Scholar
  • 70 Abdulredha W. Effect of Clenbuterol using as weight loose on lipid profile and liver enzymes. Iraq Med J 2021; 3. Available at: https:// www.iraqmedj.org/index.php/imj/article/view/641
    PubMed
  • 71 Izeboud CA, Hoebe KH, Grootendorst AF. et al. Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. Inflamm Res 2004; 53: 93-99
    CrossrefPubMedGoogle Scholar
  • 72 Abdulredha WS. Effect of Clenbuterol using as weight loose on liver enzymes and lipids profile. Iraq Med J 2019; 3. Available at: https:// www.iraqmedj.org/index.php/imj/article/view/641
    PubMed
  • 73 Stromme SB, Meen HD, Aakvaag A. Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males. Med Sci Sports 1974; 6: 203-208
    PubMedGoogle Scholar
  • 74 Fontana K, Campos GER, Staron RS. et al. Effects of anabolic steroids and high-intensity aerobic exercise on skeletal muscle of transgenic mice. PloS One 2013; 8: e80909
    CrossrefPubMedGoogle Scholar
  • 75 Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006; 147: S269-S276
    CrossrefPubMedGoogle Scholar
  • 76 Gutman M, Couillard S, Roy J. et al. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 2002; 99: 273-278
    CrossrefPubMedGoogle Scholar
  • 77 Johnson RE, Murad MH. Gynecomastia: Pathophysiology, evaluation, and management. Mayo Clinic proceedings 2009; 84: 1010-1015
    CrossrefPubMedGoogle Scholar
  • 78 Milionis HJ, Liberopoulos EN, Elisaf MS. Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus. Diabetes Metab 2001; 27: 160-163
    PubMedGoogle Scholar
  • 79 Singh HK, Prasad MS, Kandasamy AK. et al. Tamoxifen-induced hypertriglyceridemia causing acute pancreatitis. J Pharmacol Pharmacother 2016; 7: 38-40
    CrossrefPubMedGoogle Scholar
  • 80 Liu H, Bravata DM, Olkin I. et al. Systematic review: The effects of growth hormone on athletic performance. Ann Intern Med 2008; 148: 747-758
    CrossrefPubMedGoogle Scholar
  • 81 Colao A, Vitale G, Pivonello R. et al. The heart: An end-organ of GH action. Eur J Endocrinol 2004; 151: S93-S101
    CrossrefPubMedGoogle Scholar
  • 82 Colao A. The GH–IGF-I axis and the cardiovascular system: Clinical implications. Clin Endocrinol (Oxf) 2008; 69: 347-358
    CrossrefPubMedGoogle Scholar
  • 83 Miranda EJ, McIntyre IM, Parker DR. et al. Two deaths attributed to the use of 2,4-dinitrophenol. J Anal Toxicol 2006; 30: 219-222
    CrossrefPubMedGoogle Scholar
  • 84 Grundlingh J, Dargan PI, El-Zanfaly M. et al. 2,4-dinitrophenol (DNP): A weight loss agent with significant acute toxicity and risk of death. J Med Toxicol 2011; 7: 205-212
    PubMedGoogle Scholar
  • 85 MYTHS AND FACTS ABOUT HUMAN GROWTH HORMONE, B-12, AND OTHER SUBSTANCES. (2008). In Internet: https://www.govinfo.gov/ content/pkg/CHRG-110hhrg47428/html/CHRG-110hhrg47428.htm; (December 20, 2021)
    PubMed
  • 86 Waight M, McGuinness W. Case of low dose clenbuterol toxicity. BMJ Case Rep 2016; 2016 DOI: 10.1136/bcr-2016-215157.
    CrossrefPubMedGoogle Scholar
  • 87 Wibowo E, Pollock PA, Hollis N. et al. Tamoxifen in men: A review of adverse events. Andrology 2016; 4: 776-788
    CrossrefPubMedGoogle Scholar
  • 88 Grundlingh J, Dargan PI, El-Zanfaly M. et al. 2,4-dinitrophenol (DNP): A weight loss agent with significant acute toxicity and risk of death. J Med Toxicol 2011; 7: 205-212
    CrossrefPubMedGoogle Scholar
  • 89 Sheffield-Moore M, Urban RJ, Wolf SE. et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999; 84: 2705-2711
    PubMedGoogle Scholar
  • 90 Fox M, Minot AS, Liddle GW. Oxandrolone: a potent anabolic steroid of novel chemical configuration. J Clin Endocrinol Metab 1962; 22: 921-924
    CrossrefPubMedGoogle Scholar
  • 91 Karim A, Ranney RE, Zagarella J. et al. Oxandrolone disposition and metabolism in man. Clin Pharmacol Ther 1973; 14: 862-869
    CrossrefPubMedGoogle Scholar
  • 92 Petróczi A, Ocampo JAV, Shah I. et al. Russian roulette with unlicensed fat-burner drug 2,4-dinitrophenol (DNP): Evidence from a multidisciplinary study of the internet, bodybuilding supplements and DNP users. Subst Abuse Treat Prev Policy 2015; 10: 39-39
    CrossrefPubMedGoogle Scholar